Key Findings:  Cannabis-based medicine likely has a favorable risk-benefit ratio in epilepsy and chronic noncancer pain, but for most other conditions the evidence is weak or inconclusive.
Type of Study:  Meta-analysis
Study Sample Size:  198
Study Result:  Inconclusive
Study Location(s):  United States
Year of Pub:  2021
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified), Pharma THC, Pharma CBD
Phytocannabinoid Source:  Not Applicable